Purpose: Cyclooxygenase-2 (COX-2) plays important roles in the modulation of apoptosis, angiogenesis, immune response, and tumor invasion. Elevated COX-2 expression has been reported to be correlated with reduced survival after radiotherapy. This study examined whether genetic variations in the COX-2 gene are associated with different survival in inoperable locally advanced non-small cell lung cancer (NSCLC) treated with chemoradiotherapy or radiotherapy alone.
Two isoforms, COX-1 and COX-2, have been identified. COX-1 is constitutively expressed in normal tissues, which is thought to be responsible for multiple physiologic functions (5) . COX-2 is usually undetectable but is rapidly induced by various stress-related stimulations, including cytokines, growth factors, and irradiation (4, 5) . It has been shown that COX-2 plays a significant role in carcinogenesis, which is thought to modulate cellular adhesion and apoptosis, stimulate angiogenesis, and suppress immune response (6) (7) (8) . Overexpression of COX-2 has been reported in many malignancies including NSCLC, suggesting its involvement in pulmonary tumorigenesis (9) (10) (11) . Increased COX-2 expression is also associated with more aggressive tumor behavior and poor prognosis in NSCLC patients (12) . Interestingly, recent reports found that elevated COX-2 expression is correlated with reduced survival in both breast cancer and cervix carcinoma after radiotherapy (13, 14) . These observations suggest that COX-2 may also play a part in patient survival after ionizing radiation. Moreover, COX-2 inhibitors have been reported to have radiosensitizing and chemosensitizing activities both in vitro (15, 16) and in vivo (17, 18) . Therefore, reduced COX-2 expression may predict response to radiotherapy and act as a prognostic factor for locally advanced NSCLC survival.
Several functional single nucleotide polymorphisms (SNP) in the COX-2 gene have been identified, which may contribute to different gene expression or different enzyme activities (19) (20) (21) and, thus, could at least partially contribute to individual variability in arachidonic acid metabolism. Our previous studies have identified several functional COX-2 SNPs in Chinese population. We showed that some of them are associated with increased risk of malignancies, including esophageal cancer and pancreatic cancer (20) (21) (22) (23) . These SNPs include −1290A/G (rs689465), −1195G/A (rs689466), and −765G/C (rs20417) in the promoter region; 1759G/A (rs3218625) in exon 10; and 8473T/C (rs5275) in the 3′ untranslated region of the gene. Although some COX-2 SNPs, such as the 8473T/C polymorphisms, are significantly associated with NSCLC risk (24, 25) . However, little is known about their prognostic effects on NSCLC.
As a potential prognostic factor, the concept of germline variation is appealing, especially for inoperable patients. Because only a little blood sample is needed for the test, genotyping of germline variation is more practical and useful in the clinical practice. Recently, several studies have shown associations between host genetic polymorphisms and survival of NSCLC (26) (27) (28) . In this setting, genetic variations in the COX-2 gene that alter gene expression and/or protein activity may be potential candidates to predict prognosis and treatment response in NSCLC. Here, we performed a cohort study to elucidate whether functional SNPs in the COX-2 gene, alone or in combination, are associated with a biologically different survival advantage in inoperable locally advanced NSCLC treated with chemoradiation or radiation alone.
Materials and Methods
Patients. Between January 2004 and December 2007, patients with unresectable and locally advanced stage IIIA-B NSCLC were recruited at the Cancer Hospital, Chinese Academy of Medical Sciences (Beijing). The eligible patients were those with histologically or cytologically confirmed NSCLC; with measurable lesions; with Karnofski performance status (KPS) of ≥70; and with normal results of complete blood counts, liver function, and urinalysis. Patients with malignant pleural effusion were excluded. Pretreatment staging involved a thorough history and physical examination, chest X-ray, and computed tomography scans of the chest and upper abdomen, with the adjunctive use of magnetic resonance imaging or positron emission tomography scanning when available.
All the patients underwent thoracic radiation with or without platinum-based chemotherapy. None of them received epidermal growth factor receptor-or vascular endothelial growth factor receptor-targeted therapy as their systemic treatment. In the conventional radiotherapy group, the field area contained the primary tumor plus the ipsilateral hilum, the mediastinum superior, or entire mediastinum. In the three-dimensional conformal radiotherapy group, only the primary tumor and positive lymph node-draining area, with a short axis diameter of at least 1 cm on computed tomography or fluorodeoxyglucose uptake on positron emission tomography, were included in the clinical target area. A total dose of 40 to 70 Gy was given with 2 Gy per fraction, 5 d weekly. In fact, the original dose prescription was no less than 60 Gy. However, there were four patients whose actual dose prescriptions were below 60 Gy. The detailed information was as follows: two patients received <60 Gy (40 and 
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50 Gy, respectively) because of severe radiation-induced pneumonitis and two patients received 50 Gy because of progressive disease during radiation. The toxicity was graded according to the Common Terminology Criteria for Adverse Events v3.0. Survival information was collected every 3 mo from hospital medical records and/or by phone.
A total of 144 patients agreed to participate in this study and had adequate blood DNA for genotyping and 136 had complete follow-up and clinical information. There was no significant difference in the distributions of demographic information between patients enrolled and patients who did not. Written informed consent was obtained from each patient for the use of their DNA and clinical information. The study was approved by the Institutional Review Board of the Cancer Institute and Hospital.
SNP genotyping. Genomic DNA was extracted from 5-mL blood sample that was collected from each patient upon recruitment. The COX-2 −1290A/G, −1195G/A, −765G/C, 1759G/A, and 8473T/C polymorphisms were genotyped by PCR-based RFLP methods as previously described (21, 29) . Genotypes were confirmed by direct DNA sequencing of the PCR products. A 15% blind, random sample of study subjects was genotyped twice by different persons (N. Bi and M. Yang) and the reproducibility was 100%.
Statistical analysis. For each polymorphism, the HardyWeinberg equilibrium was tested by the Pearson χ 2 test. Student's t test or χ 2 test was used to calculate the difference of patient clinical characteristics. OS was calculated as the time to death from the date of diagnosis. Progressionfree survival (PFS) was calculated as the time to progression or death without progression from the date of diagnosis. Survival distributions were estimated with the Kaplan-Meier method and were compared with the logrank test. Multivariate Cox proportional hazards models were applied to estimate the effect of prognostic factors on OS and PFS, using proverbial clinical factors, including age, sex, smoking status, KPS, weight loss, histology, clinical stages, radiation technique and dosage, and chemotherapy. Statistical significance was set at a level of 0.05 and all the analyses were done using the SPSS software package (version 11.5, SPSS, Inc.).
Results
Patient characteristics and clinical outcomes. The distribution of demographic and clinical characteristics of patients is presented in Table 1 . By the time of the final analysis (February 2009), the median follow-up time of the patients was 22.4 months. One hundred and seventeen patients (86.0%) died and the median survival time was 18.1 months (range, 2.7-60.3 months). The 1-, 2-, 4-, and 5-year OS rates were 74%, 34%, 13%, and 7%, respectively.
Comparison of survival according to baseline characteristics of patients. To test whether various clinical characteristics contribute to survival, patients were grouped according to age, sex, smoking status, KPS, weight loss, histology, clinical stages, or treatment parameters. Both OS and PFS were compared among different groups. For OS, only radiation technique significantly influenced patient prognosis (P = 0.001). The median OS for patients who had undergone three-dimensional radiotherapy (3D-RT) Abbreviations: 2D-RT, two-dimensional radiotherapy; GTV, gross tumor volume. *Others include large cell carcinoma and adenosquamous carcinoma.
was 6 months longer than that of patients undergone two-dimensional radiotherapy (18.9 months versus 13.9 months). However, other baseline characteristics did not affect OS (all P > 0.05). In addition, PFS was not influenced by any patient characteristics and treatment (Table 3) . Effects of SNPs on OS and PFS. The allelic frequencies for the COX-2 variants are summarized in Table 2 . All observed genotype frequencies in patients conformed to the Hardy-Weinberg equilibrium. No statistical associations were observed between any of these polymorphisms and age, sex, smoking status, KPS, weight loss, histology, clinical stages, or treatment parameters (data not shown).
Interestingly, the COX-2 -1195G/A polymorphism was significantly associated with patient survival. As shown in Table 2 , patients with the −1195GG genotype had 12 months longer survival [median OS, 27.7 months; 95% confidence interval (CI), 21.3-34.1 months) than those with the −1195AA genotypes (median OS, 15.7 months; 95% CI, 12.1-19.3 months; P = 0.0016 for log-rank test). Moreover, the median OS for patients with the −1195GA + GG genotypes (median OS, 20.2 months, 95% CI, 14.4-26.0 months) was also significantly longer than that for patients with the AA genotype (median OS, 15.7 months; 95% CI, 12.1-19.3 months; P = 0.006 for log-rank test; Fig. 1A) . Similarly, significant difference in PFS was observed in lung cancer patients related to −1195G/A genotypes (P = 0.034 for log-rank test; Table 2 ; Fig. 1B) . The median PFS for the −1195 AA genotype and GA + GG genotypes were 9.5 months and 11.9 months, respectively.
Because 75.0% of NSCLC patients in this cohort also underwent chemotherapy, we further examined whether the association between the COX-2 −1195G/A SNP and survival could be influenced by different treatments. As shown in Fig. 2 , the median OS of the −1195AA genotype was shorter than that of the −1195GA + GG genotypes both in patients treated with chemoradiation (median OS, 15.9 months versus 18.9 months; P = 0.04 for logrank test) and in patients treated with radiation alone (median OS, 14.7 months versus 24.8 months; P = 0.09 for log-rank test). We further tested whether this association between the polymorphism and OS still existed in patients treated with concurrent chemoradiation and the results were also positive (median OS, 15.0 months versus 20.2 months; P = 0.03 for log-rank test). There were no associations between the other four COX-2 polymorphisms and OS or PFS. However, it is notable that the variant CC and TC genotypes of the 3′ untranslated region 8473T/C SNP showed a tendency to be associated with poor OS compared with the TT genotype, although the association was not statistically significant (median OS, 14.7 months versus 20.4 months; P = 0.15 for logrank test).
Multivariate analysis. In the multivariate Cox proportional hazards model, after adjustment for the clinicopathologic factors including age, sex, smoking status, KPS, weight loss, histology, clinical stages, chemotherapy, or radiation dosage, the prognostic significance of both COX-2 −1195G/A polymorphism and radiation technique still existed (both P = 0.008; Table 3 ). The hazard ratios (HR) of patients with the −1195GA + GG genotypes or treated with 3D-RT on OS were 0.58 (95% CI, 0.39-0.87) and 0.47 (95% CI, 0.27-0.82).
Discussion
In the present study, we examined whether genetic polymorphisms in the COX-2 gene are associated with survival in a cohort of 136 locally advanced NSCLC patients treated with chemoradiotherapy or radiotherapy alone. We found that the AA genotype of −1195G/A SNP in the COX-2 promoter region significantly contributed to poor OS and PFS compared with the −1195GG genotype. After adjusting for clinicopathologic factors, the COX-2−1195G/A variant was still significantly associated with OS, showing that the −1195G/A polymorphism was an independent survival predictor. Additionally, 3D-RT was also independently associated with OS of NSCLC patients in the cohort. Fig. 1 . Kaplan-Meier curve of estimated (A) OS (P = 0.006 for log-rank test) and (B) PFS (P = 0.034 for log-rank test) for the entire cohort with different COX-2 −1195G/A genotypes. Fig. 2 . Kaplan-Meier curve of estimated OS for the patients with different COX-2 −1195G/A genotypes receiving (A) chemoradiation (P = 0.04 for log-rank test), (B) radiation alone (P = 0.09 for log-rank test), or (C) concurrent chemoradiation (P = 0.03 for log-rank test).
It was shown that inhibition of COX-2 enzyme with selective inhibitors enhances tumor response to radiation and chemotherapeutic agents (30). Pyo et al. (31) showed that, compared with drug nontreated tumorbearing control mice, selective COX-2 inhibitors enhanced the effect of radiation on tumors that express COX-2, such as NCI-H460 cells, but not on COX-2-lacking tumors. An association between COX-2 expression and responses to radiation has also been observed in patients with cervical or breast cancer (32, 33) .
Although our and other's studies found that the COX-2 SNPs were related to elevated risk of several cancers, including lung cancer (24, 34) , few have been done to investigate if the COX-2 SNPs are associated with cancer survival (32). Iglesias et al. (35) have recently reported that the c.3618A/G (rs4648298) polymorphism located in the 3′ flanking regions of COX-2 was associated with improved survival of colorectal cancer patients in Caucasians. However, in our previous study, it was shown that c.3618A/G (rs4648298) variant was not a common polymorphism in Han Chinese population (major allele frequency, <0.05; ref. 21) . Therefore, we did not include this polymorphism in the current study. To the best of our knowledge, this is the first study showing that the COX-2 variants could predict survival in patients with lung cancer. Our previous functional study showed that the −1195G to A change creates a c-MYB binding site in the COX-2 promoter region and, thus, displays a higher promoter activity (21) . Compared with the −1195G-containing counterparts, the −1195AA carriers showed significantly increased COX-2 expression in vitro and in vivo. In addition, elevated expression of COX-2 has been reported in NSCLC (12, (36) (37) (38) and was associated with an invasive and more aggressive phenotype (36) . Consequently, our observations are biologically plausible and consistent with these previous reports, showing that functional −1195G/A SNP, which may influence the expression of COX-2, leads to decreased survival in NSCLC independently.
Few studies have been reported thus far with regard to different COX-2 polymorphisms and clinical outcomes of patients with NSCLC. Vogel et al. (39) showed a gene-drug interaction between the COX-2 −1195G/A SNP and COX-2 inhibitor use in enhancing lung cancer risk. The COX-2 −1195A allele was also associated with a poor response to vinorelbine-based chemotherapy in patients with NSCLC (40) . All these observations suggest that the COX-2 −1195G/A polymorphism plays an essential role in cancer development and might be a useful molecular indicator of lung cancer risk, prognosis, and response to treatment.
Our results showed that stage III NSCLC with the COX-2 −1195AA genotype might be more aggressive and probably more radiation resistant than those with the −1195GA + GG genotypes. Therefore, a personalized more intensive treatment, i.e., a combination treatment of chemoradiotherapy and COX-2 inhibitor, might be warranted to improve the survival in patients with the unfavorable COX-2 −1195AA genotype. Several phase II studies failed to show the value of eicosanoid inhibition in addition to other modalities, such as chemotherapy, and/or tyrosine kinase inhibitor target therapy, in unselected population of advanced NSCLC (35, 38, (41) (42) (43) . However, recent evidence suggested a potential advantage for celecoxib, a selective COX-2 inhibitor, might be obtained in the certain population (44, 45) . A prospective randomized clinical trail, CALGB 30203, showed that patients with moderate to high expression of COX-2 had a worse OS than those with low expression (HR, 2.51; 95% CI, 1.14-5.56; P = 0.019). More interestingly, combined use of COX-2 inhibitor could improve the OS of these patients significantly (HR, 0.342; 95% CI, 0.155-0.752; P = 0.005; ref. 44) . Similarly, we found that the unfavorable COX-2 −1195AA genotype, which results in increased COX-2 expression, was also associated with poor OS. Therefore, this genetic variant could be a novel and helpful predictive factor to identify specific NSCLC patients who may benefit from COX-2 inhibitors. Because almost all of advanced NSCLC patients are inoperatable and their tumor specimens are not Limitations of this study include its moderate sample size and retrospective design. Before being confirmed by well-designed, larger prospective studies, results from this study should not be overinterpreted. Clinical trials examining COX-2 SNPs in patients treated with conventional therapy combined with COX-2 inhibitors may help to clarify if COX-2 −1195G/A polymorphism could act as a predictive marker of COX-2 target therapy. Moreover, because some genetic markers are ethnic specific, our results also should be validated among different ethnic populations in the future.
In conclusion, we have reported for the first time that there were significant differences in the OS and PFS among NSCLC patients with different COX-2 −1195G/A genotypes. Our results suggest that in addition to measures of clinicopathologic factors, the naturally occurring genetic variants in the COX-2 gene might be useful clinical predictive factors in patients with inoperable locally advanced NSCLC receiving thoracic radiotherapy with or without chemotherapy.
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